
MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

